Tokyo - Delayed Quote JPY

Tsumura & Co. (4540.T)

3,496.00
-21.00
(-0.60%)
At close: May 23 at 3:30:00 PM GMT+9
Loading Chart for 4540.T
  • Previous Close 3,517.00
  • Open 3,516.00
  • Bid 3,496.00 x --
  • Ask 3,505.00 x --
  • Day's Range 3,491.00 - 3,528.00
  • 52 Week Range 3,316.00 - 5,138.00
  • Volume 617,300
  • Avg. Volume 542,210
  • Market Cap (intraday) 263.028B
  • Beta (5Y Monthly) 0.03
  • PE Ratio (TTM) 8.18
  • EPS (TTM) 427.21
  • Earnings Date Aug 4, 2025 - Aug 8, 2025
  • Forward Dividend & Yield 136.00 (3.89%)
  • Ex-Dividend Date Sep 29, 2025
  • 1y Target Est 4,758.00

Tsumura & Co. manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally. The company offers Kampo extract intermediates, granular and prescription Kampo formulations, over-the-counter Kampo medicine, other medications, and herbal bath salts. It offers its products for female problems, proneness to fatigue, skin problems, gastrointestinal problems, obesity, constipation, hemorrhoid, body aches, cold, cough, nasal/throat inflammation, children's sickness, stress, and urinary problems. Tsumura & Co. was founded in 1893 and is headquartered in Tokyo, Japan.

www.tsumura.co.jp

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 4540.T

View More

Performance Overview: 4540.T

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4540.T
24.60%
Nikkei 225 (^N225)
6.85%

1-Year Return

4540.T
7.63%
Nikkei 225 (^N225)
4.97%

3-Year Return

4540.T
28.56%
Nikkei 225 (^N225)
37.62%

5-Year Return

4540.T
40.57%
Nikkei 225 (^N225)
82.26%

Compare To: 4540.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4540.T

View More

Valuation Measures

Annual
As of 5/22/2025
  • Market Cap

    263.03B

  • Enterprise Value

    261.72B

  • Trailing P/E

    8.23

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.47

  • Price/Book (mrq)

    0.88

  • Enterprise Value/Revenue

    1.45

  • Enterprise Value/EBITDA

    4.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.91%

  • Return on Assets (ttm)

    5.62%

  • Return on Equity (ttm)

    11.04%

  • Revenue (ttm)

    181.09B

  • Net Income Avi to Common (ttm)

    32.43B

  • Diluted EPS (ttm)

    427.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    73.23B

  • Total Debt/Equity (mrq)

    21.31%

  • Levered Free Cash Flow (ttm)

    251M

Research Analysis: 4540.T

View More

Company Insights: 4540.T

Research Reports: 4540.T

View More

People Also Watch